Compare AIV & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | CMPX |
|---|---|---|
| Founded | 1975 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.7M | 408.8M |
| IPO Year | 1996 | 2020 |
| Metric | AIV | CMPX |
|---|---|---|
| Price | $2.42 | $2.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $14.57 |
| AVG Volume (30 Days) | 969.2K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 87.41% | N/A |
| EPS Growth | ★ 616.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,486,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.46 | $1.61 |
| 52 Week High | $8.03 | $6.88 |
| Indicator | AIV | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 26.67 | 38.72 |
| Support Level | N/A | $1.88 |
| Resistance Level | $2.74 | $2.08 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 4.55 | 1.96 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.